

June 14, 1965

Dr. Vincent Y. Cremata, Jr.
Associate Director of Clinical Research
Chas. Pfizer & Co., Inc.
Department of Clinical Research
Medical Research Laboratories
Groton, Connecticut

Dear Dr. Cremata:

Some weeks ago you were kind enough to send us the information regarding P-4657B, as well as the report by Dr. Arthur Sugerman. My associates and I have reviewed the information concerning this compound and then discussed this with Dr. Crane.

Insofar as our population is limited in size, it is difficult for us to launch a study of this compound at the present time. It does interest us, however, and I have asked Dr. Crane to invite us to the meeting which he plans to hold when the other scientists studying this compound will report their results, hopefully later this summer. For the meanwhile, I am writing to indicate that we are not able to proceed with a specific study.

Thank you for sending us the information.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp